Type 2 diabetes patients who used imeglimin as an add-on to metformin treatment showed better fasting plasma glucose and proinsulin/insulin ratio compared with those on metformin-placebo therapy, according to a study in Diabetes Care. Metformin-imeglimin treatment was generally well-tolerated and showed a similar safety profile to that of metformin-placebo treatment, researchers said.

Related Summaries